IKT Inhibikase Therapeutics, Inc.

NASDAQ
$1.53

Inhibikase Therapeutics, Inc. (IKT) is expected to report earnings on February 9, 2027, after the market close. The consensus earnings estimate is a loss of $0.11 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.9% since its last earnings release on November 10, 2026.

Inhibikase Therapeutics Beat Consensus Estimates
Tuesday, November 10, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 9
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.11)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.57

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.